Pulmonary Arterial Hypertension Therapeutics
1. Adempas patent expiration
Treatment: Treatment of adults with pulmonary hypertension (pah), (who group 1), to improve exercise capacity, who functional class and to delay clinical worsening
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents protects the active chemical substance. Only drug patent owner can launch products that use this active substance. | ||||
| US6743798 | BAYER HLTHCARE | Substituted pyrazole derivatives condensed with six-membered heterocyclic rings |
Jul, 2019
(6 years ago) | |
| US10662188 | BAYER HLTHCARE | Forms of methyl {4,6-diamino-2-[1 (2-fluorobenzyl)-1H-pyrazolo[3-4-b]pyridino-3-yl]pyrimidino-5-yl} methyl carbamate |
Feb, 2034
(8 years from now) | |
| US11203593 | BAYER HLTHCARE | Forms of methyl {4,6-diamino-2-[1(2-fluorobenzyl)-1H-pyrazolo[3-4-b]pyridino-3-yl]pyrimidino-5-yl}methyl carbamate |
Feb, 2034
(8 years from now) | |
| US7173037 | BAYER HLTHCARE | Carbamate-substituted pyrazolopyridines |
Dec, 2026
(10 months from now) | |
| Drug Exclusivity | Drug Exclusivity Expiration |
|---|---|
| New Chemical Entity Exclusivity(NCE) | Oct 08, 2018 |
| Orphan Drug Exclusivity(ODE) | Oct 08, 2020 |
| Orphan Drug Exclusivity(ODE-53) | Oct 08, 2020 |
Drugs and Companies using RIOCIGUAT ingredient
NCE-1 date: 08 October, 2017
Market Authorisation Date: 08 October, 2013
Dosage: TABLET
How can I launch a generic of ADEMPAS before it's drug patent expiration?
More Information on Dosage
ADEMPAS family patents
2. Cialis patent expiration
Treatment: Erectile dysfunction; Treatment of erectile dysfunction; Treatment of sexual dysfunction
CIALIS IPR and PTAB Proceedings
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
|
US6943166 (Pediatric) | LILLY | Compositions comprising phosphodiesterase inhabitors for the treatment of sexual disfunction |
Oct, 2020
(5 years ago) | |
| US6821975 | LILLY | Beta-carboline drug products |
Nov, 2020
(5 years ago) | |
| US6140329 | LILLY | Use of cGMP-phosphodiesterase inhibitors in methods and compositions to treat impotence |
Jul, 2016
(9 years ago) | |
| US7182958 | LILLY | β-carboline pharmaceutical compositions |
Apr, 2020
(5 years ago) | |
|
US5859006 (Pediatric) | LILLY | Tetracyclic derivatives; process of preparation and use |
May, 2018
(7 years ago) | |
|
US6821975 (Pediatric) | LILLY | Beta-carboline drug products |
May, 2021
(4 years ago) | |
| US5859006 | LILLY | Tetracyclic derivatives; process of preparation and use |
Nov, 2017
(8 years ago) | |
|
US7182958 (Pediatric) | LILLY | β-carboline pharmaceutical compositions |
Oct, 2020
(5 years ago) | |
| US6943166 | LILLY | Compositions comprising phosphodiesterase inhabitors for the treatment of sexual disfunction |
Apr, 2020
(5 years ago) | |
| Drug Exclusivity | Drug Exclusivity Expiration |
|---|---|
| New Indication(I-641) | Oct 06, 2014 |
| New Indication(I-642) | Oct 06, 2014 |
| M(M-219) | Feb 15, 2021 |
| Pediatric Exclusivity(PED) | Aug 15, 2021 |
Drugs and Companies using TADALAFIL ingredient
Market Authorisation Date: 07 January, 2008
Dosage: TABLET
How can I launch a generic of CIALIS before it's drug patent expiration?
More Information on Dosage
CIALIS family patents
3. Letairis patent
expiration
Treatment: Method to treat pulmonary hypertension by administering ambrisentan to a patient; Treatment of pulmonary arterial hypertension by inhibiting...
LETAIRIS's oppositions filed in EPO
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US5703017 | GILEAD | 3-(Het) arylcarboxylic acid derivatives, their preparation and intermediates for their preparation |
Dec, 2014
(11 years ago) | |
| US7601730 | GILEAD | Carboxylic acid derivatives, their preparation and use |
Oct, 2015
(10 years ago) | |
| USRE42462 | GILEAD | Carboxylic acid derivatives, their preparation and use |
Jul, 2018
(7 years ago) | |
| US7109205 | GILEAD | Carboxylic acid derivatives, their preparation and use |
Oct, 2015
(10 years ago) | |
| US5840722 | GILEAD | Use of carboxylic acid derivatives as drugs |
Nov, 2015
(10 years ago) | |
| US8349843 | GILEAD | Carboxylic acid derivatives, their preparation and use |
Oct, 2015
(10 years ago) | |
| US9474752 | GILEAD | Method for treating a pulmonary hypertension condition |
Dec, 2027
(1 year, 11 months from now) | |
| US9549926 | GILEAD | Compositions and methods of treating pulmonary hypertension |
Oct, 2031
(5 years from now) | |
| US8377933 | GILEAD | Method for treating a pulmonary hypertension condition |
Dec, 2027
(1 year, 11 months from now) | |
| Drug Exclusivity | Drug Exclusivity Expiration |
|---|---|
| New Chemical Entity Exclusivity(NCE) | Jun 15, 2012 |
| Orphan Drug Exclusivity(ODE) | Jun 15, 2014 |
| New Indication(I-716) | Oct 02, 2018 |
Drugs and Companies using AMBRISENTAN ingredient
NCE-1 date: 16 June, 2011
Market Authorisation Date: 15 June, 2007
Dosage: TABLET
How can I launch a generic of LETAIRIS before it's drug patent expiration?
More Information on Dosage
LETAIRIS family patents
4. Opsumit patent expiration
Treatment: Method of treating pulmonary hypertension comprising administering macitentan in combination with a compound having phosphodiesterase-5 inhibitory properties; Method of treating
OPSUMIT IPR and PTAB Proceedings
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents protects the active chemical substance. Only drug patent owner can launch products that use this active substance. | ||||
| US7094781 | ACTELION | Sulfamides and their use as endothelin receptor antagonists |
Dec, 2025
(a month ago) | |
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US8268847 | ACTELION | Therapeutic compositions comprising a specific endothelin receptor antagonist and a PDE5 inhibitor |
Apr, 2029
(3 years from now) | |
| US9265762 | ACTELION | Stable pharmaceutical compositions comprising a pyrimidine-sulfamide |
May, 2027
(1 year, 4 months from now) | |
| US10946015 | ACTELION | Stable pharmaceutical compositions comprising a pyrimidine-sulfamide |
Sep, 2026
(8 months from now) | |
| US8367685 | ACTELION | Stable pharmaceutical compositions comprising a pyrimidine-sulfamide |
Oct, 2028
(2 years from now) | |
|
US8268847 (Pediatric) | ACTELION | NA |
Oct, 2029
(3 years from now) | |
|
US7094781 (Pediatric) | ACTELION | NA |
Jun, 2026
(4 months from now) | |
|
US8367685 (Pediatric) | ACTELION | NA |
Apr, 2029
(3 years from now) | |
|
US9265762 (Pediatric) | ACTELION | NA |
Nov, 2027
(1 year, 10 months from now) | |
|
US10946015 (Pediatric) | ACTELION | NA |
Mar, 2027
(1 year, 2 months from now) | |
| Drug Exclusivity | Drug Exclusivity Expiration |
|---|---|
| New Chemical Entity Exclusivity(NCE) | Oct 18, 2018 |
| Orphan Drug Exclusivity(ODE) | Oct 18, 2020 |
| Orphan Drug Exclusivity(ODE-54) | Oct 18, 2020 |
| M(M-187) | Feb 28, 2028 |
| Pediatric Exclusivity(PED) | Aug 28, 2028 |
Drugs and Companies using MACITENTAN ingredient
NCE-1 date: 29 August, 2027
Market Authorisation Date: 18 October, 2013
Dosage: TABLET
How can I launch a generic of OPSUMIT before it's drug patent expiration?
More Information on Dosage
OPSUMIT family patents
5. Remodulin patent expiration
Treatment: Administration of remodulin diluted for intravenous infusion with sterile diluent for flolan or sterile diluent for epoprostenol sodium prior to administration; Treatment of pulmonary hypertension wit...
REMODULIN's oppositions filed in EPO
REMODULIN IPR and PTAB Proceedings
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents protects the active chemical substance. Only drug patent owner can launch products that use this active substance. | ||||
| US8497393 | UNITED THERAP | Process to prepare treprostinil, the active ingredient in Remodulin® |
Dec, 2028
(2 years from now) | |
| US9593066 | UNITED THERAP | Process to prepare treprostinil, the active ingredient in remodulin® |
Dec, 2028
(2 years from now) | |
| US11723887 | UNITED THERAP | Process to prepare treprostinil, the active ingredient in Remodulin® |
Dec, 2028
(2 years from now) | |
| US9604901 | UNITED THERAP | Process to prepare treprostinil, the active ingredient in Remodulin® |
Dec, 2028
(2 years from now) | |
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US8658694 | UNITED THERAP | Buffer solutions having selective bactericidal activity against gram negative bacteria and methods of using same |
Sep, 2028
(2 years from now) | |
| US5153222 | UNITED THERAP | Method of treating pulmonary hypertension with benzidine prostaglandins |
Oct, 2014
(11 years ago) | |
| US6765117 | UNITED THERAP | Process for stereoselective synthesis of prostacyclin derivatives |
Oct, 2017
(8 years ago) | |
| US8653137 | UNITED THERAP | Buffer solutions having selective bactericidal activity against gram negative bacteria and methods of using same |
Sep, 2028
(2 years from now) | |
| US7999007 | UNITED THERAP | Buffer solutions having selective bactericidal activity against gram negative bacteria and methods of using same |
Mar, 2029
(3 years from now) | |
| US9199908 | UNITED THERAP | Compounds and methods for delivery of prostacyclin analogs |
May, 2024
(1 year, 7 months ago) | |
| US9713599 | UNITED THERAP | Parenteral formulations of treprostinil |
Dec, 2024
(1 year, 23 days ago) | |
| US10695308 | UNITED THERAP | Inhalation formulations of treprostinil |
Dec, 2024
(1 year, 23 days ago) | |
| US10076505 | UNITED THERAP | Inhalation formulations of Treprostinil |
Dec, 2024
(1 year, 23 days ago) | |
Drugs and Companies using TREPROSTINIL ingredient
Market Authorisation Date: 28 September, 2023
Dosage: INJECTABLE; SOLUTION
How can I launch a generic of REMODULIN before it's drug patent expiration?
More Information on Dosage
REMODULIN family patents
6. Tracleer patent expiration
Treatment: NA
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US5292740 | ACTELION | Sulfonamides |
Nov, 2015
(10 years ago) | |
| US8309126 | ACTELION | Dispersible bosentan tablet |
May, 2026
(4 months from now) | |
| US7959945 | ACTELION | Dispersible bosentan tablet |
Dec, 2027
(1 year, 11 months from now) | |
| Drug Exclusivity | Drug Exclusivity Expiration |
|---|---|
| New Indication(I-607) | Aug 07, 2012 |
| New Product(NP) | Sep 05, 2020 |
| New Patient Population(NPP) | Sep 05, 2020 |
| Orphan Drug Exclusivity(ODE) | Sep 05, 2024 |
| ODE*(ODE*) | Sep 05, 2024 |
| Orphan Drug Exclusivity(ODE-161) | Sep 05, 2024 |
Drugs and Companies using BOSENTAN ingredient
Market Authorisation Date: 20 November, 2001
Dosage: TABLET; TABLET, FOR SUSPENSION
How can I launch a generic of TRACLEER before it's drug patent expiration?
More Information on Dosage
TRACLEER family patents
7. Uptravi patent expiration
Treatment: Method of treating pulmonary arterial hypertension comprising administering selexipag in combination with the endothelin receptor antagonist...
UPTRAVI's oppositions filed in EPO
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents protects the active chemical substance. Only drug patent owner can launch products that use this active substance. | ||||
| US7205302 | ACTELION | Heterocyclic compound derivatives and medicines |
Oct, 2026
(9 months from now) | |
| US8791122 | ACTELION | Form-I crystal of 2-{4-[N-(5,6-diphenylpyrazin-2-yl)-N-isopropylamino]butyloxy}-N-(methylsulfonyl)acetamide and method for producing the same |
Aug, 2030
(4 years from now) | |
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US9173881 | ACTELION | Therapeutic compositions containing macitentan |
Aug, 2029
(3 years from now) | |
| US9284280 | ACTELION | Use of form-I crystal of 2-{4-[N-(5,6-diphenylpyrazin-2-yl)-N-isopropylamino]butyloxy}-N-(methylsulfonyl)acetamide |
Jun, 2030
(4 years from now) | |
| US10828298 | ACTELION | Pharmaceutical composition containing 2-{4-[N-(5,6-diphenylpyrazin-2-yl)-N-isopropylamino]butyloxy]-N-(methylsulfonyl)acetamide |
Dec, 2036
(10 years from now) | |
| US10821108 | ACTELION | Pharmaceutical composition containing 2-{4-[N-(5,6-diphenylpyrazin-2-yl)-N-isopropylamino]butyloxy}-N-(methylsulfonyl)acetamide |
Dec, 2036
(10 years from now) | |
| Drug Exclusivity | Drug Exclusivity Expiration |
|---|---|
| New Chemical Entity Exclusivity(NCE) | Dec 21, 2020 |
| Orphan Drug Exclusivity(ODE) | Dec 21, 2022 |
| Orphan Drug Exclusivity(ODE-106) | Dec 21, 2022 |
Drugs and Companies using SELEXIPAG ingredient
NCE-1 date: 22 December, 2019
Market Authorisation Date: 21 December, 2015
Dosage: TABLET; POWDER
How can I launch a generic of UPTRAVI before it's drug patent expiration?
More Information on Dosage
UPTRAVI family patents